..:: Learn the latest news ::..

Other News Added

:: 29 May 2005
Human Trials Announced for Adult Stem Cell Spinal Fusion
Melbourne, Australia; 18 December 2006: Australia’s adult stem cell company, Mesoblast Limited (ASX:MSB), today...

Melbourne, Australia; 18 December 2006: Australia’s adult stem cell company, Mesoblast Limited (ASX:MSB), today announced that the United States Food and Drug Administration (US FDA) has cleared its Investigational New Drug Submission (IND) to commence a Phase 2 clinical trial for spinal fusion in the US.
Human Trials Announced for Adult Stem Cell Spinal Fusion

:: 29 May 2005
Stem Cell Trial for Heart Attack Approved by FDA
Australia’s adult stem cell company, Mesoblast Limited has announced that the United States...

Australia’s adult stem cell company, Mesoblast Limited has announced that the United States Food and Drug Administration (US FDA) has cleared the Investigational New Drug Submission (IND) of its US-based sister company, Angioblast Systems Inc., to commence a Phase 2 clinical trial of its allogeneic, or ‘off-the-shelf’, adult stem cells for patients with heart attacks. The Phase 2 clinical trial will be based at the Texas Heart Institute, and will follow a similar protocol to the one used by the same investigators in preclinical studies for the IND submission. These showed that implantation of the company’s proprietary allogeneic stem cells by catheter into damaged heart muscle resulted in significant improvement in heart function and reduction in congestive heart failure. This clinical trial will be the first to test an allogeneic stem cell product injected by catheter into heart muscle damaged by a recent heart attack. The trial will use the latest generation catheters provided through Angioblast’s ongoing relationship with the Johnson
Stem Cell Trial for Heart Attack Approved by FDA

:: 14 May 2007
Clinical trials to test for the efficacy of autologous bone marrow derived mononuclear cell therapies in four different cardiopathies: acute and chronic ischemic heart disease, and Chagasic and dilated cardiomyopathy.

:: 14 May 2007
Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study: a multicenter, prospective, randomized, single-blind trial comparing early and late intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of nonselected autologous bone marrow cells to patients after acute myocardial infarction.

Future use of adult stem cells: In the future, it may be possible for a person to use a sample of his or her own stem cells to regenerate tissue, which would reduce or even eliminate the danger of rejection. How might this be done? Some possibilities include:

• Collecting healthy adult stem cells from a patient and manipulating them in the laboratory to create new tissue. The tissue would be re-transplanted back into the patient's body, where it would work to restore a lost function.
• Therapeutic cloning might enable the creation of embryonic stem cells that are genetically identical to the patient.
• One less invasive way to achieve this goal would be to manipulate existing stem cells within the body to perform therapeutic tasks. For example, scientists might design a drug that would direct a certain type of stem cell to restore a lost function inside the patient's body. This approach would eliminate the need for invasive surgical procedures to harvest and transplant stem cells.